News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
175,317 Results
Type
Article (16988)
Company Profile (45)
Press Release (158284)
Section
Business (57685)
Career Advice (900)
Deals (9288)
Drug Delivery (29)
Drug Development (23164)
Employer Resources (70)
FDA (2259)
Job Trends (4175)
News (91251)
Policy (5739)
Tag
Academia (476)
Africa (323)
Alabama (12)
Allergies (11)
Alliances (16036)
Alzheimer's disease (316)
Antibody-drug conjugate (ADC) (38)
Approvals (2235)
Arizona (18)
Artificial intelligence (31)
Asia (13053)
Australia (2575)
Bankruptcy (75)
Best Places to Work (2734)
Biosimilars (10)
C2C Services and Suppliers (7886)
California (333)
Canada (225)
Cancer (74)
Career advice (728)
CAR-T (28)
Cell therapy (43)
China (23)
Clinical research (17369)
Collaboration (37)
Connecticut (14)
COVID-19 (694)
Cystic fibrosis (25)
Diagnostics (972)
Diversity, equity & inclusion (21)
Drug pricing (10)
Earnings (14944)
Employer resources (65)
Europe (28994)
Events (29628)
Executive appointments (16)
FDA (2268)
Florida (23)
Funding (29)
Gene editing (15)
Gene therapy (25)
GLP-1 (203)
Government (579)
Healthcare (2323)
Hotbed/Location (113653)
Idaho (12)
Illinois (62)
Indiana (26)
Infectious disease (698)
Inflammatory bowel disease (38)
Interviews (131)
IPO (3984)
Job creations (1464)
Job search strategy (691)
Kansas (16)
Layoffs (108)
Legal (1159)
Liver cancer (12)
Lung cancer (14)
Management (19)
Manufacturing (23)
Maryland (63)
Massachusetts (123)
Medical device (661)
Medtech (661)
Mergers & acquisitions (5248)
Metabolic disorders (57)
Neuroscience (354)
New Jersey (14)
New York (21)
NextGen Class of 2024 (1383)
Non-profit (444)
North Carolina (56)
Obesity (33)
Opinion (146)
Patents (15)
Peanut (10)
Pennsylvania (15)
People (21276)
Phase I (6761)
Phase II (8293)
Phase III (4705)
Policy (14)
Postmarket research (298)
Preclinical (2758)
Rare diseases (35)
Real estate (2423)
Recruiting (35)
Regulatory (4174)
Reports (10)
Research institute (513)
Resumes & cover letters (144)
Series A (15)
South America (395)
Startups (1763)
Texas (15)
United States (916)
Vaccines (118)
Washington State (63)
Weight loss (37)
Date
Today (1)
Last 7 days (159)
Last 30 days (641)
Last 365 days (13083)
2024 (7606)
2023 (13201)
2022 (16038)
2021 (16924)
2020 (13174)
2019 (9493)
2018 (7536)
2017 (8980)
2016 (8120)
2015 (9412)
2014 (9724)
2013 (9448)
2012 (6079)
2011 (6451)
2010 (5841)
175,317 Results for "aurion biotech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Aurion Biotech CEO Greg Kunst Named Ernst & Young 2024 Entrepreneur of the Year Mountain West Region
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced that CEO Greg Kunst has been named winner of the Ernst & Young 2024 Entrepreneur of the Year award for the Mountain West Region.
June 17, 2024
·
3 min read
BioForest
Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001
Aurion Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation for AURN001, the Company’s allogeneic cell therapy candidate for the treatment of corneal edema secondary to corneal endothelial disease.
June 19, 2024
·
4 min read
Drug Development
Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial
Aurion Biotech today announced that it has completed dosing of all subjects in its Phase 1 / 2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
April 30, 2024
·
3 min read
BioForest
Aurion Biotech to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Aurion Biotech today announced several presentations during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.
April 2, 2024
·
3 min read
Drug Development
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
Aurion Biotech today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.
March 28, 2024
·
3 min read
BioForest
Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By BioTech Breakthrough
Aurion Biotech announced it has been selected as “Regenerative Therapeutics Company of the Year” in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
November 8, 2023
·
4 min read
Business
Greg Kunst, CEO of Aurion Biotech, Receives Healthcare Leadership Award from Puget Sound Business Journal
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced that CEO Greg Kunst has won one of the Healthcare Leadership awards from the Puget Sound Business Journal.
December 7, 2023
·
2 min read
Drug Development
Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial
Aurion Biotech today announced that it has dosed the first subject in its Phase 1 / 2 U.S. clinical trial (ABA-1, CLARA) of AURN001.
October 24, 2023
·
3 min read
Policy
Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application
Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for its novel cell therapy, Vyznova™, for the treatment of bullous keratopathy of the cornea.
March 23, 2023
·
7 min read
BioForest
Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced several presentations during the 2023 American Society of Cataract and Refractive Surgery Annual Meeting to be held May 5-8, 2023 in San Diego, California.
May 2, 2023
·
3 min read
1 of 17,532
Next